Inspira Technologies Oxy BHN (IINN)
NASDAQ:IINN
Top Page
Inspira Technologies Oxy BHN
(NASDAQ:IINN)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.70
▼(-27.50% Downside)
Action:ReiteratedDate:01/06/26
The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.
Positive Factors
Standalone HYLA validation expands TAM
Decoupling HYLA from Inspira’s life-support hardware creates a standalone product that can plug into existing OR/ICU workflows, opening a much larger $50B addressable market. The design enables recurring high-margin sensor disposables and software upgrades, improving long-term revenue visibility and gross-margin potential.
Negative Factors
Persistent unprofitable core operations
The company’s core products have not yet generated positive gross margins, producing consistent net losses and undermining internal funding sources. Negative gross profit means unit economics are adverse; absent quick margin improvement, the business will remain reliant on external capital, limiting sustainable R&D and commercial scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Standalone HYLA validation expands TAM
Decoupling HYLA from Inspira’s life-support hardware creates a standalone product that can plug into existing OR/ICU workflows, opening a much larger $50B addressable market. The design enables recurring high-margin sensor disposables and software upgrades, improving long-term revenue visibility and gross-margin potential.
Read all positive factors
Inspira Technologies Oxy BHN (IINN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.13M
Dividend YieldN/A
Average Volume (3M)330.47K
Price to Earnings (P/E)―
Beta (1Y)1.91
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,271,835
10 Day Avg. Volume227,613
30 Day Avg. Volume330,466
Financial Highlights & Ratios
PEG Ratio17.10
Price to Book (P/B)4.37
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue37.48
Enterprise Value/Gross Profit5.42K
Enterprise Value/Ebitda-1.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)$48.00M
Inspira Technologies Oxy BHN Business Overview & Revenue Model
Company Description
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the ...
How the Company Makes Money
Inspira Technologies Oxy BHN generates revenue primarily through the sale and distribution of its proprietary medical devices, particularly the ART system. The company targets hospitals and healthcare facilities as its primary customers, offering ...
Inspira Technologies Oxy BHN Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
46
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 289.00K | 0.00 | 0.00 | -4.68M | 0.00 | 0.00 |
| Gross Profit | 2.00K | -488.00K | -406.00K | -5.04M | -218.00K | -203.00K |
| EBITDA | -7.16M | -11.10K | -10.87M | -14.68M | -16.72M | -6.96M |
| Net Income | -6.40M | -11.05K | -11.29M | -4.00M | -16.96M | -7.23M |
Balance Sheet | ||||||
| Total Assets | 4.45M | 8.07M | 9.31M | 16.01M | 25.87M | 987.00K |
| Cash, Cash Equivalents and Short-Term Investments | 2.13M | 5.78M | 7.36M | 13.90M | 23.75M | 496.00K |
| Total Debt | 640.00K | 2.51M | 878.00K | 1.46M | 1.48M | 2.32M |
| Total Liabilities | 3.17M | 3.75M | 3.57M | 3.19M | 5.52M | 2.69M |
| Stockholders Equity | 1.28M | 4.32M | 5.74M | 13.63M | 20.35M | -1.70M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -9.54M | -9.96M | -7.68M | -8.05M | -1.90M |
| Operating Cash Flow | 0.00 | -9.37M | -9.76M | -7.38M | -7.88M | -1.88M |
| Investing Cash Flow | 0.00 | 1.49M | 4.59M | -7.25M | -246.00K | -26.00K |
| Financing Cash Flow | 0.00 | 7.90M | 3.45M | -399.00K | 30.42M | 2.29M |
Inspira Technologies Oxy BHN Technical Analysis
Negative
0.96
Price Trends
0.65
Negative
0.82
Negative
0.99
Negative
Market Momentum
-0.03
Negative
28.00
Positive
10.55
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IINN, the sentiment is Negative. The current price of 0.96 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.65, and below the 200-day MA of 0.99, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 28.00 is Positive, neither overbought nor oversold. The STOCH value of 10.55 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IINN.
Inspira Technologies Oxy BHN Risk Analysis
Inspira Technologies Oxy BHN disclosed 70 risk factors in its most recent earnings report. Inspira Technologies Oxy BHN reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inspira Technologies Oxy BHN Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.48B | 27.15 | -21.49% | ― | 8.97% | -1024.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $144.74M | -4.35 | -32.46% | ― | 15.19% | -3.32% | |
46 Neutral | $7.27M | -0.21 | -279.58% | ― | 147.74% | 73.23% | |
46 Neutral | $52.37M | -2.19 | -82.79% | ― | 15.59% | 4.13% | |
44 Neutral | $37.69M | -4.85 | -91.54% | ― | -8.97% | 47.29% | |
42 Neutral | $22.13M | -1.78 | -279.06% | ― | ― | ― |
* Healthcare Sector Average
IINN
Inspira Technologies Oxy BHN
0.51
-0.20
-28.03%
CTSO
Cytosorbents
0.60
-0.40
-40.00%
LIVN
LivaNova
63.65
24.03
60.65%
XAIR
Beyond Air
0.69
-4.93
-87.73%
NNOX
Nano-X Imaging
2.27
-3.19
-58.42%
LUNG
Pulmonx
1.24
-5.55
-81.74%
Inspira Technologies Oxy BHN Corporate Events
Inspira Technologies Validates Standalone HYLA Blood Sensor, Targeting $50 Billion Heart-Lung Surgery Market
Feb 3, 2026
On February 3, 2026, Inspira Technologies announced it has successfully validated its next-generation standalone HYLA blood sensor system in advanced blood labs, demonstrating 94.2% accuracy in continuous optical measurement of pCO₂ at a lev...
Inspira Technologies’ ART100 Completes Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center
Jan 29, 2026
On January 29, 2026, Inspira Technologies announced that its FDA-cleared INSPIRA ART100 system has completed full clinical evaluation and progressed into a budgeted procurement execution process at a leading U.S. academic medical center ranked amo...
Inspira Technologies Nears Final Government Approval for $49.5 Million in Purchase Orders
Jan 21, 2026
On January 21, 2026, Inspira Technologies announced that two previously disclosed binding purchase orders worth $22.5 million and $27 million, first reported on July 2 and August 19, 2025, have progressed to the final budgetary validation and fund...
Inspira Technologies Sets CVR-Backed Deal Structure for Breast Cancer Liquid Biopsy Expansion
Jan 8, 2026
On January 8, 2026, Inspira Technologies outlined a strategic vision and proposed transaction framework for expanding into breast cancer liquid biopsy diagnostics through the acquisition of an advanced platform focused on circulating tumor cells, ...
Inspira Technologies Moves Into Liquid Biopsy With Planned Acquisition and $15 Million Strategic Investment
Jan 5, 2026
On January 5, 2026, Inspira Technologies Oxy B.H.N. Ltd. signed a non-binding term sheet to acquire an advanced liquid biopsy cancer diagnostics business in an all-share deal, exchanging 40% of its fully diluted share capital and securing a concur...
Inspira Technologies Confirms Shareholder Approval After Adjourned December 30 Meeting
Dec 31, 2025
Inspira Technologies Oxy B.H.N. Ltd., an Israeli foreign private issuer listed in the United States, operates within the medical technology and healthcare sector, though this filing focuses on its corporate governance and regulatory compliance rat...
Inspira Technologies Reaffirms $49.5 Million Orders, Shifts Execution to 2026 Milestones
Dec 23, 2025
On December 23, 2025, Inspira Technologies Oxy B.H.N. Ltd. reaffirmed that previously announced binding purchase orders totaling $49.5 million remain valid and in full force, based on confirmations from its distribution partner. The company said t...
Inspira Technologies Secures $1.8 Million in Direct Offering and Equity Financing
Dec 15, 2025
On December 12, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced a registered direct offering agreement with YA II PN, Ltd., involving the issuance of 1,565,217 ordinary shares at $1.15 per share, expected to generate $1.8 million in gross pro...
Inspira Technologies Secures Japanese Patent for Innovative Cannula Device
Dec 9, 2025
On December 9, 2025, Inspira Technologies announced that it has been granted a patent in Japan for its Convertible Dual Lumen Cannula device, securing exclusive rights in a major medical device market until 2041. This patent complements their exis...
Inspira Technologies Expands Lab Capabilities for Growth
Dec 3, 2025
On December 3, 2025, Inspira Technologies announced a strategic expansion of its blood laboratory capabilities, marking a significant step in its evolution towards cutting-edge diagnostic technologies. This expansion involves moving to a larger fa...
Inspira Technologies Announces Annual and Extraordinary General Meeting for December 2025
Nov 25, 2025
Inspira Technologies Oxy B.H.N. Ltd. has announced its upcoming Annual and Extraordinary General Meeting of Shareholders, scheduled for December 30, 2025, in Ra’anana, Israel. The meeting will address several key proposals, including the re-...
Inspira Technologies Completes Clinical Study for HYLA Blood Sensor
Nov 13, 2025
On November 13, 2025, Inspira Technologies announced the completion of a clinical study for its HYLA blood sensor, a non-invasive device designed for real-time blood monitoring. The study showed accuracy levels between 95% to 99%, and the company ...
Inspira Technologies Awaits Final Approval for ART100 in UAE
Nov 6, 2025
On November 6, 2025, Inspira Technologies announced the completion of its regulatory submission for the ART100 system to the UAE Ministry of Health and Prevention, with final approval expected soon. This milestone is part of Inspira’s strate...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.